12-Month retrospective study and review of photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in age-related macular degeneration

Retina

Volumn 28, Issue 2, 2008, Pages 289-297

  Incorvaia, Carlo ^a   Campa, Claudio ^a   Parmeggiani, Francesco ^a   Menzione, Massimo ^b   D'Angelo, Sergio ^a   Corte, Michele Della ^b   Rinaldi, Michele ^b   Romano, Mary ^b   Dell'Omo, Roberto ^c   Costagliola, Ciro ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Age related macular degeneration; Photodynamic therapy with verteporfin; Subfoveal choroidal neovascularization

Indexed keywords

VERTEPORFIN; PHOTOSENSITIZING AGENT; PORPHYRIN;

ADULT; AGED; BACKACHE; CONTROLLED STUDY; EYE DISCOMFORT; FEMALE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; ARTICLE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; MIDDLE AGED; PHOTOCHEMOTHERAPY; RETINA FOVEA; RETINA MACULA DEGENERATION; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 42449112181     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31813ffe90     Document Type: Review

References (39)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;8:844-851.
2. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004;137:486-495.
3. Macular Photocoagulation Study (MPS) Group. Evaluation of argon green vs krypton red laser for photocoagulation of subfoveal choroidal neovascularization in the macular photocoagulation study. Arch Ophthalmol 1994;112:1176-1184.
4. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-134.
5. Wickens J, Blinder KJ. A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration. Drug Saf 2006;29:189-199.
6. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660-668.
7. Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214.
8. Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H. Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 2002;43:830-841.
9. Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci 2003;44:2147-2154.
10. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials-TAP report no. 1. Arch Ophthalmol 1999;117:1329-1345.
11. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 2 year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - VIP report no. 2. Am J Ophthalmol 2001;131:541-560.
12. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in agerelated macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: TAP and VIP report no. 4. Retina 2004;24:1-12.
13. Essex RW, Qureshi SH, Cain MS, et al. Photodynamic therapy in practice: a review of the results of the first 12 months experience with verteporfin at the Royal Victorian Eye and Ear Hospital. Clin Experiment Ophthalmol 2003;31:476-481.
14. Japanese Age-Related Macular Degeneration Trial (JAT) Study Group. Japanese age-related macular degeneration trial: 1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:1049-1061.
15. Barnes RM, Gee L, Taylor S, et al. Outcomes in verteporfin photodynamic therapy for choroidal neovascularization - "beyond the TAP study." Eye 2004;18:809-813.
16. Bressler NM. VAM Study Writing Committee. Verteporfin therapy in age-related macular degeneration (VAM): an open-label multicenter photodynamic therapy study of 4,435 patients. Retina 2004;24:512-520.
17. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457.
18. Nicolo M, Ghiglione D, Lai S, et al. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 2006;26:58-64.
19. Ergun E, Maar N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol 2006;142:10-16.
20. Dhalla MS, Shah GK, Blinder KJ, et al. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006;26:988-993.
21. Arias L, Garcia-Arumi J, Ramon JM, et al. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006;113:2243-2250.
22. Liggett PE, Colina J, Chaudhry NA, et al. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006;142:1072-1074.
23. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin photodynamic therapy, bevacizumab, and dexamethasone. Retina 2007;27:133-140.
24. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007;10:141-148.
25. Macular Photocoagulation Study (MPS) Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the Macular Photocoagulation Study. Arch Ophthalmol 1991;109:1242-1257.
26. Verteporfin Roundtable 2000 and 2001 Participants; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group Principal Investigators; Verteporfin in Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.
27. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no. 2. Arch Ophthalmol 2003;121:1253-1268.
28. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-1196.
29. Macular Photocoagulation Study (MPS) Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993;111:1200-1209.
30. Maguire M. Natural history. In: Berger JW, Fine SL, Maguire M, eds. Age-Related Macular Degeneration. 1st ed. St. Louis: Mosby; 1999:17-30.
31. Armbrecht AM, Aspinall PA, Dhillon B. A prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration. Br J Ophthalmol 2004;88:1270-1273.
32. Frennesson CI, Nilsson SE. Encouraging results of photodynamic therapy with Visudyne in a clinical patient material of age-related macular degeneration. Acta Ophthalmol Scand 2004;82:645-650.
33. Wachtlin J, Stroux A, Wehner A, et al. Photodynamic therapy with verteporfin for choroidal neovascularisations in clinical routine outside the TAP study. One- and two-year results including juxtafoveal and extrafoveal CNV. Graefes Arch Clin Exp Ophthalmol 2005;243:438-445.
34. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 2003;136:407-418.
35. Axer-Siegel R, Ehrlich R, Yassur Y, et al. Photodynamic therapy for age-related macular degeneration in a clinical setting: visual results and angiographic patterns. Am J Ophthalmol 2004;137:258-264.
36. Sivaprasad S, Saleh GM, Jackson H. Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration? Eye 2006;20:43-45.
37. Potter MJ, Szabo SM, Li WW. Comparison of visual acuity outcomes in predominantly classic vs occult lesions in age-related macular degeneration treated with photodynamic therapy [Epub ahead of print]. Eye September 1, 2006.
38. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
39. Rosenfeld PJ, Brown DM, Heier JS, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.